Biomedical Structures LLC, a developer of biomaterials and textiles for medical devices and other advanced clinical applications is working in cooperation with fiber manufacturer DSM Dyneema as a proven specialist in processing its Dyneema Purity, including the recently launched Dyneema Purity BLUE fiber, for various biomedical textile applications in orthopedic and cardiovascular devices.
Dyneema Purity BLUE is the first 100% colored implantable grade Ultra High Molecular Weight Polyethylene (UHMWPE) fiber in the world, and will enable innovative new additions to BMS’ biomedical textile capabilities.
A provider of technical materials for biomedical applications, BMS specializes in the design and manufacturing of crafted and nonwoven specialty fabrics for orthopedic, cardiovascular and tissue engineering applications, including implantable devices such as tissue scaffolds and woven vascular grafts, components for surgical procedures, and drug delivery tools.BMS is already an established processor of DSM’s Dyneema Purity, and the unique strength and distinctive color of Dyneema Purity BLUE will allow the company to design high-strength sutures alone or in dual combination without the need to use colored polyester or nylon.By providing color contrast without sacrificing strength, applications will provide improved performance and better ease-of-use for physicians differentiating between multiple sutures during arthroscopic and various other surgeries.
“As DSM Dyneema continues to develop innovative materials for the medical community, we are excited to be working with Biomedical Structures, one of the industry’s foremost experts in medical textile design and manufacturing,” said Carina Snijder, business manager medical for DSM Dyneema. “Combining the unmatched quality and strength of Dyneema Purity with Biomedical Structures’ extensive experience in processing Dyneema Purity for use in medical devices, device companies will soon be in a position to leverage next generation applications to work more confidently and effectively and ultimately help surgeons and improve patient outcomes.”